Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

9 Mar 2018 15:00 News

A collaboration between healthcare solutions provider, Novartis, and Pear Therapeutics has been announced that aims to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (MS). more

7 Mar 2018 12:30 Technology

Novartis has formed an alliance with the Bill & Melinda Gates Foundation to further develop its drug candidate, KDU731, for the treatment of cryptosporidiosis — a cause of infectious diarrhoea in children. more

15 Feb 2018 14:07 News

Novartis plans to transition the use of its treatment for certain chronic lymphocytic leukaemia (CLL), Arzerra (ofatumumab), from commercial availability to limited availability via compassionate use programmes in all markets except the US. more

22 Jan 2018 09:54 News

Two recently published clinical studies have demonstrated a new approach using antibodies to target specific chemicals in the brain may help significantly reduce the incidence and severity of migraines. more

30 Nov 2017 11:01 News

Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more

16 Nov 2017 12:32 News

Novartis has announced a collaboration with biotech company, Homology Medicines, to adapt and refine the technology for the treatment of a blood disorder and certain eye diseases. more

14 Nov 2017 13:43 News

Swiss-based pharma group Helsinn has revealed its US subsidiary (Helsinn Therapeutics) has signed a co-promotion agreement with Novartis for Zykadia more

7 Sep 2017 08:53 News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

1 Sep 2017 13:58 News

Novartis has received approval for its chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, from the US Food and Drug Administration (FDA). more

31 Aug 2017 14:59 News

Primary data from the CANTOS Phase III trial (sponsored by Novartis) has revealed that a treatment that targets inflammation reduces the risk of cardiovascular disease. more

29 Aug 2017 16:26 News

A recently published report, sponsored by Novartis, has described the potential benefits of the NHS only paying for drugs that actually work as a new model to address affordability and reduce risks within the health system. more

27 Jul 2017 11:52 Analysis

Today, the FDA will convene the Oncologic Drugs Advisory Committee to review Novartis’ personalised cancer therapy, CTL019. The first discussion point of the meeting will focus on manufacturing and product quality control more

12 Jul 2017 12:57 News

Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via the Novartis Facebook, Twitter, Instagram and LinkedIn channels more

11 May 2017 12:04 News

The FDA has granted breakthrough therapy designation to Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019 more

19 Apr 2017 11:43 News

Novartis has focussed its pharmaceutical division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology, that will together function as the Innovative Medicine Division at Novartis more

26 May 2016 09:13 News

Novartis has established FortiHFy, a global clinical programme, to generate additional data on the effects of the company’s novel heart failure medicine, Entrestro more

19 May 2016 12:35 News

The heart failure market is set to rise by £5.8bn ($8.6bn) within the next century, according to GlobalData more

3 May 2016 12:25 News

Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases more

18 Apr 2016 11:56 News

Novartis and the National Institute for Health Research (NIHR) Translational Research Partnership are investigating how omalizumab can be targeted to better treat asthma patients more

24 Mar 2016 11:38 News